US20030130652A1 - Cryosurgical ablation device having sequential injection and method therefor - Google Patents
Cryosurgical ablation device having sequential injection and method therefor Download PDFInfo
- Publication number
- US20030130652A1 US20030130652A1 US10/371,023 US37102303A US2003130652A1 US 20030130652 A1 US20030130652 A1 US 20030130652A1 US 37102303 A US37102303 A US 37102303A US 2003130652 A1 US2003130652 A1 US 2003130652A1
- Authority
- US
- United States
- Prior art keywords
- cryogenic fluid
- valves
- fluid
- tip
- cryogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000002347 injection Methods 0.000 title claims abstract description 55
- 239000007924 injection Substances 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims abstract description 28
- 238000002679 ablation Methods 0.000 title claims abstract description 16
- 239000012530 fluid Substances 0.000 claims abstract description 151
- 210000001519 tissue Anatomy 0.000 claims description 20
- 238000004891 communication Methods 0.000 claims description 11
- 206010003119 arrhythmia Diseases 0.000 claims description 5
- 230000006793 arrhythmia Effects 0.000 claims description 4
- 210000005003 heart tissue Anatomy 0.000 claims description 3
- 238000013507 mapping Methods 0.000 claims description 3
- 230000011664 signaling Effects 0.000 claims 2
- 238000010586 diagram Methods 0.000 description 8
- 230000003902 lesion Effects 0.000 description 7
- 238000001816 cooling Methods 0.000 description 6
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- RWRIWBAIICGTTQ-UHFFFAOYSA-N difluoromethane Chemical compound FCF RWRIWBAIICGTTQ-UHFFFAOYSA-N 0.000 description 2
- 239000001272 nitrous oxide Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000013153 catheter ablation Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- GTLACDSXYULKMZ-UHFFFAOYSA-N pentafluoroethane Chemical compound FC(F)C(F)(F)F GTLACDSXYULKMZ-UHFFFAOYSA-N 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- -1 polydimethylsiloxane Polymers 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0212—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques using an instrument inserted into a body lumen, e.g. catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0231—Characteristics of handpieces or probes
- A61B2018/0262—Characteristics of handpieces or probes using a circulating cryogenic fluid
Definitions
- the present invention relates to cryosurgical tissue ablation, and in particular, to a device and method which increases the effective freezing length in the device tip while simultaneously maintaining a usable device size and safe operating characteristics.
- Radio frequency energy, microwave energy, laser energy, extreme heat and extreme cold can be provided by the ablation device to kill the tissue.
- Certain procedures such as cardiac procedures, are performed by selectively ablating the tissue.
- cardiac procedures are performed by selectively ablating the tissue.
- the cardiac tissue is selectively ablated to eliminate the source of the arrhythmia.
- RF radio frequency
- cryoablation has been used as has cryoablation in which the RF and cryogenic devices are arranged to provide very limited spot-sized lesions.
- these conventional devices are not well suited for tissue ablation along a length, i.e. larger than a spot-sized lesion.
- a series of spot ablation lesions are created by moving the device tip located at the distal end of the device along the length to be ablated.
- the device typically includes a single cryogenic fluid lumen. Use of this arrangement can be time consuming, thereby prolonging procedure duration, and can result in an uneven ablation, reducing the effectiveness of the procedure. It would therefore be desirable to have a cryosurgical device that provides enhanced cooling capability for spot lesions, as well as the capability to create other than spot lesions.
- the present invention provides a device that provides enhanced cooling capability for spot lesions and the capability to create other than spot lesions, as well as a method for ablating tissue.
- the device includes a tip having a thermally transmissive region along a length thereof.
- the thermally transmissive region is operable at a temperature sufficient to cryosurgically ablate tissue in contact therewith.
- Fluid injection lumens are positioned within device so that the ends of the lumens are at different points along the length of the thermally transmissive region. Each of the ends are arranged to cool overlapping portions along the length of the thermally transmissive region when cryogenic fluid is ejected from the the fluid injection lumens.
- a cryosurgical tip is positioned at tissue to be ablated, the tip having a thermally transmissive region along a length thereof.
- Cryogenic fluid is sequentially injected into the tip through multiple cryogenic fluid injection lumens terminating within the tip at different points along the length of the thermally transmissive region.
- FIG. 1 is a schematic illustration of a cryosurgical system utilizing a cryogenic cooling structure constructed in accordance with the principles of the present invention
- FIG. 2 is a diagram of a side view of an exemplar catheter arranged in accordance with the principles of the present invention
- FIG. 3 is a block diagram of an arrangement of longitudinally spaced injection lumens and their corresponding cryogenic fluid control valves
- FIG. 4 is a block diagram of an integrated fluid provisioning unit
- FIG. 5 is a block diagram of a two port cryogenic fluid valve assembly
- FIG. 6 is a cut away side view of an integrated fluid provisioning unit positioned within the inner volume of a handle;
- FIG. 7 is a cut away side view of an alternate arrangement of the present invention of thumbscrews positioned within the inner volume of a handle;
- FIGS. 8 A-E show diagrammatic views of the thermally transmissive tip region at various times during the sequential operation of the valves.
- FIG. 1 a schematic illustration of a cryosurgical system utilizing a cryogenic cooling structure constructed in accordance with the principles of the present invention.
- the system includes a fluid controller 10 coupled to the proximal end 12 of a catheter 14 .
- the controller 10 allows or causes cryogenic fluid to flow from a cryogenic fluid supply (not shown) through the proximal end 12 of the catheter 14 to a thermally transmissive tip region 16 positioned at the distal end of the catheter 14 .
- the fluid controller 10 is responsive to an input from a foot pedal or other human actuable switch to permit the flow of cryogenic fluid into the catheter 14 .
- One or more temperature sensors in electrical communication with the controller 10 can be provided to regulate or terminate the flow of cryogenic fluid into the catheter 14 by a predetermined temperature at a selected point or points on or within the catheter such as in thermally transmissive region 16 is obtained.
- the cryogenic fluid can be in a liquid or a gas state.
- An extremely low temperature can be achieved within the thermally transmissive region 16 by cooling the fluid to a predetermined temperature prior to its introduction into the catheter 14 , by allowing a liquid state cryogenic fluid to boil or vaporize, or by allowing a gas state cryogenic fluid to expand.
- Exemplary liquids include chlorodifluoromethane, polydimethylsiloxane, ethyl alcohol, HFCs such as AZ-20 (a 50-50 mixure of difluoromethane and pentafluoroethane sold by Allied Signal), nitrous oxide, and CFCs such as DuPont's Freon.
- Exemplary gases include nitrous oxide and carbon dioxide.
- FIG. 2 is a diagram of a side view of an exemplar catheter 14 arranged in accordance with the principles of the present invention.
- the catheter 14 preferably includes an electrical connector 18 and a mechnaical connector 20 coupled to the thermally transmissive region 16 via a flexible segment 24 .
- the electrical connector 18 is coupled to the controller 10 and provides external connection points for electronic signals such as cryogenic fluid valve activation signals, ECG signals, temperature sensing signals and the like.
- the cryogenic connector 20 preferably has an input opening 26 by which cryogenic fluid is input into the catheter 14 and a cryogenic output opening 28 by which the cryogenic fluid is evacuated from the catheter 14 .
- the handle 22 is gripped by the user during operation and includes those control elements necessary for the user to “steer” the catheter inside the patient's body. Further, the handle 22 an be arranged to define an inner volume in which cryogenic fluid valves are located. The arrangement and operation of the cryogenic fluid valves are discussed below in detail.
- Flexible segment 24 is generally arranged to include an outer fluid and gas impermeable sheath inside of which one or more flexible cryogenic fluid (or vapor) lumen are disposed for carrying the cryogenic fluid from the controller 10 to the thermally transmissive region 16 and returning it.
- the outer flexible sheath includes a return lumen or defines a volume for use as the return path for cryogenic fluid from the thermally transmissive region 16 to the cryogenic output opening 28 .
- Arrangements for providing a cryogenic fluid return lumen or using all or a portion of an inner volume of the flexible segment 24 as a return path for cryogenic fluid are known.
- the cryogenic fluid is provided via the controller 10 to the cryogenic fluid input opening 26 .
- the cryogenic fluid is circulated through the handle 22 , through the flexible segment 24 to the thermally transmissive tip region 16 where the fluid expands, boils, etc., thereby cooling the thermally transmissive region 16 .
- the spent vapor is returned through the flexible segment 24 , through the handle 22 and out the cryogenic fluid output opening 28 .
- the catheter 14 is preferably arranged to include a plurality of cryogenic fluid injection lumens having respective openings longitudinally spaced at different points along the length L of the thermally transmissive region 16 .
- the plurality of injection lumens can be individually arranged to span the entire length of the catheter 14 from the input opening 26 to the thermally transmissive region 16 or can be arranged as a single injection lumen from the input opening 26 to a cryogenic fluid distribution element provided in the handle 22 .
- FIG. 3 shows a block diagram of an arrangement of the plurality of longitudinally spaced injection lumens and their corresponding cryogenic fluid control valves. Initially, it is noted that although FIG. 3 and the subsequent figures are arranged to show two or four injection lumens, it is contemplated that any quantity of injection lumen can be used subject to the desired length of the thermally transmissive region 16 , the maximum acceptable diameter of the flexible segment 24 for a particular application and the cryogenic fluid input capacity of the system.
- the injection lumens 30 a , 30 b , 30 c and 30 d couple the cryogenic fluid valve assembly 32 to the thermally transmissive region 16 at the tip of catheter 14 .
- Each of the injection lumens 30 a - 30 d terminate at a different point along length L within the thermally transmissive region 16 or the shaft 24 .
- the injection lumen 30 a is the longest injection lumen, terminating substantially at the distal end of the catheter 14 .
- the injection lumen 30 b is shorter than the injection lumen 30 a
- the injection lumen 30 c is shorter than the injection lumen 30 b
- the injection lumen 30 d is shorter than the injection lumen 30 c such that it is positioned at a point along the length L within the thermally transmissive region 16 closer to the handle 22 than the injection lumens 30 a - c.
- the cryogenic fluid valve assembly 32 is preferably comprised of an assembly fluid input 34 for each of the injection lumen (shown as assembly fluid inputs 34 a , 34 b , 34 c and 34 d in FIG. 3) in fluid communication with a corresponding assembly fluid output 36 (shown as assembly fluid outputs 36 a , 36 b , 36 c and 36 d in FIG. 3) via a corresponding valve 38 (shown as valves 38 a , 38 b , 38 c and 38 d in FIG. 3).
- Each of the assembly fluid outputs 36 a - 36 d is coupled to and is in fluid communication with a corresponding injection lumen 30 a - 30 d .
- Each of the valves 38 a - 38 d are individually actuable by mechanical, electrical or electromechanical operation.
- the cryogenic fluid valve assembly 32 includes a valve processor 40 which receives n electronic actuation signals via the corresponding electronic actuation signal lines 42 and where n is the number of signal lines necessary to control actuation of the valves 38 .
- the valve processor 40 can be any processing unit capable of actuating the valves 38 .
- the valves 38 can be arranged as piezo-electric valves which are actuable based on well-known piezo-electric principles. In this case, the valve processor 40 operates to control the piezo-electric effect necessary to actuate the valves 38 .
- the piezoelectric actuation method for the cryogenic fluid valve assembly 32 is preferred because the assembly 32 can be manufactured in a size small enough for placement within the handle 22 of the catheter 14 .
- any suitable method for actuating the valves 38 can be used.
- the cryogenic fluid path includes a cryogenic fluid distributor 44 having an input 46 and one or more outputs 48 (shown in FIG. 3 as outputs 48 a , 48 b , 48 c and 48 d ) corresponding to assembly fluid inputs 34 .
- the cryogenic fluid distributor 44 is preferably made of any material which can withstand cryogenic fluid temperatures and which can be manufactured in a size small enough to be positioned within the handle 22 of the catheter 14 .
- the input 46 is coupled to the cryogenic connector 20 by a tube suitable for carrying cryogenic fluid.
- FIG. 4 is a block diagram showing the integrated fluid provisioning unit 50 which includes the input 46 , the valves 38 and the assembly fluid outputs 36 .
- the integrated fluid provisioning unit 50 is preferably located within the inner volume of the handle 22 but can also be located in other system components such as the controller 10 .
- the valves can be in a distal portion of the catheter.
- FIG. 5 shows an example of a two port cryogenic fluid valve assembly 32 having two assembly fluid inputs 34 a and 34 b and two assembly fluid outputs 36 a and 36 b coupled to corresponding injection lumens 30 a and 30 b .
- Valves 38 are not shown in FIG. 5 for the sake of simplicity, it being understood that the valves 38 are included as described above with respect to the cryogenic fluid valve assembly 32 .
- corresponding input lumen 52 shown in FIG. 5 as input lumens 52 a and 52 b
- An arrangement similar to the cryogenic fluid valve assembly 32 shown in FIG. 5 is implemented in the case where the cryogenic fluid distributor 44 is positioned in the controller 10 and the cryogenic fluid valve assembly 32 is located in the handle 22 .
- FIG. 6 shows a cut away side view of an example of an integrated fluid provisioning unit 50 positioned within the inner volume 54 of a handle 22 .
- the injection lumens 30 a and 30 b couple the integrated fluid provisioning unit 50 to the thermally transmissive tip region 16 .
- a return lumen 56 is provided for evacuating the cryogenic fluid from the thermally transmissive tip region 16 for return to the fluid reservoir 10 .
- the return lumen 56 is coupled to the cryogenic output opening 28 , the electronic actuation signal lines 42 are coupled to the electrical connector 18 and the cryogenic fluid input 46 is coupled to the input opening 26 .
- cryogenic fluid distributor 44 and/or the cryogenic fluid valve assembly 32 can be located within the inner volume 54 of the handle 22 .
- FIG. 7 shows a cut away side view of an alternate arrangement of the present invention in which the cryogenic fluid flow is manually actuated by thumbscrew valves 58 a and 58 b .
- the human actuable portion of the thumbscrew valves 58 a and 58 b protrude through the outer surface of the handle 22 a as thumbscrews 60 a and 60 b , respectively.
- the thumbscrew valves 58 a and 58 b are manually adjustable by the user via a corresponding thumbscrew 60 a and 60 b to open or close the cryogenic fluid path between the input lumens 52 a and 52 b and the corresponding injection lumen 30 a and 30 b .
- the preferable arrangement is using a processor controlled electronic or electromechanical switch. The reasoning behind this preference is discussed below in detail with respect to the sequential operation of the lumens 30 in the catheter 14 .
- FIGS. 8 A- 8 E show a diagrammatic view of the thermally transmissive tip region 16 at various times during the sequential operation of the valves 38 a - 38 d .
- FIG. 8A shows the thermally transmissive tip region 16 at a state in which none of valves 38 a - 38 d have been opened, i.e. cryogenic fluid is not flowing in the injection lumens 30 a - 30 d .
- the freeze zones 62 a , 62 b , 62 c and 62 d show those areas on the surface of the thermally transmissive tip region 16 corresponding to the distal terminus of a corresponding injection lumen 30 a - 30 d . It is noted that the freeze zones 62 a - 62 d represent approximate areas along the surface of the thermally transmissive tip region 16 and do not correspond to actual elements. As such, the size and specific location of the freeze zones 62 a - 62 d can vary and are substantially related to the corresponding distal terminus of the injection lumen 30 a - 30 d.
- FIG. 8B shows cryogenic fluid in injection lumen 30 a causing a freezing condition around the freeze zone 62 a .
- the area 64 a on the exterior of the thermally transmissive tip region 16 is cooled by the ejection of the cryogenic fluid from the distal terminus of the injection lumen 30 a such that the area 64 a is cooled to an extent sufficient for the application of cryosurgical ablation.
- the valve 38 a is closed and the valve 38 b is opened, causing cryogenic fluid to be ejected from the distal end of the injection lumen 30 b in the thermally transmissive tip region 16 .
- the area 64 b around the freeze zone 62 b is created which overlaps the area 64 a and is chilled to a point sufficient for cryosurgical ablation.
- FIG. 8D and FIG. 8E are diagrams showing the expansion of the freeze area to include overlapping areas 64 c and 64 d as a result of the sequential actuation of the valves 38 c and 38 d , respectively. As shown in FIG. 8E, the resultant freeze area occupies a length L along the thermally transmissive tip region 16 .
- the freeze area along length L is advantageously accomplished by sequentially operating the valves 38 a - 38 d in a manner which does not require an excessive cryogenic fluid flow rate which would otherwise create a positive pressure inside the catheter 14 .
- the sequential operation is preferably controlled by a microprocessor or other central processing unit to electronically instruct the valve processor 40 to sequentially actuate the valves 38 a - 38 d .
- Electronic control using the valve processor 40 allows precise valve actuation control for sequencing and valve actuation duration.
- a freeze length L can be achieved using a very small cryogenic fluid flow rate as compared with known devices (3800 cubic feet per minute to achieve a 60 millimeter freeze length using a single injection lumen versus 1300 cubic centimeter per minutes cryogenic fluid flow rate to achieve a 100 millimeter freeze length L).
- the arrangement of the present invention advantageously conserves cryogenic fluid while providing an extended freeze length L as compared with known similarly sized devices.
- cryogenic fluid from one injection lumen should begin after cryogenic fluid ejection is terminated in the previous injection lumen in the sequence, but before the previous areas dislodge, i.e. thaw, from the tissue. Because the sequential application of cryogenic fluid is used, the total procedure time becomes t times m where m is the number of freezing areas (and injection tubes).
- multiple lumens can be logically grouped and activated at substantially the same time, subject to maintaining a cryogenic fluid flow rate which can be evacuated from the catheter 14 while maintaining a negative pressure within the catheter 14 .
- valves 38 a and 38 c can be opened at substantially the same time, then closed and valves 38 b and 38 d opened at substantially the same time. This technique shortens the cryoablation procedure time as compared with the discreet sequential operation of the valves 38 a - 38 d described above while still maintaining a safe operating environment, for example, 2600 cubic centimeters per minute in a 7 French size catheter.
- Another implementation of the device of the present invention permits use as a mapping and/or selective ablation zone device. Because the freeze area length along the tip of the device is extremely elongated as compared with known devices and because particular areas of the device can be selectively cooled (areas 64 a - 64 d ), the device of the present invention can be used to perform cold mapping to detect tissue regions, such as cardiac tissue regions, which if ablated will eliminate an arrhythmia. Each of areas 64 a - 64 d can be cooled to determine which areas, if any, will improve or eliminate the arrhythmia.
- the elongated freeze length L advantageously allows individual areas to be cooled without the need to relocate the thermally transmissive tip region 16 to another tissue point. Once an area is identified as suitable for ablation, the particular valve or valves 38 are opened and the specific section(s) of the thermally transmissive tip region 16 cooled. This arrangement advantageously minimizes tissue destruction such as myocardial tissue destruction and saves time by avoiding the need to repeatedly thaw and relocate the thermally transmissive tip region 16 .
- a device constructed in accordance with the principles of the present invention can take other forms, including but not limited to a rigid probe.
- the present invention advantageously provides a device and method which provides an elongated freeze length within the thermally transmissive tip region in a manner in which specific areas in the thermally transmissive tip region can be cooled or sequentially cooled to provide an elongated freeze length.
- the arrangement of the present invention is advantageously provided in a manner which maintains a usable device size and which maintains a safe operating mode by maintaining a negative pressure within the device.
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Surgical Instruments (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
Abstract
Description
- n/a
- n/a
- The present invention relates to cryosurgical tissue ablation, and in particular, to a device and method which increases the effective freezing length in the device tip while simultaneously maintaining a usable device size and safe operating characteristics.
- Advances in medical procedures have resulted in the development of procedures which use minimally invasive surgical techniques such that one or more slender implements such as probes or catheters are inserted through one or more small incisions into a patent's body. These implements include surgical ablation implements having a rigid or flexible structure in which the ablation device is located at or near the implement's distal end that is placed adjacent to the tissue to be ablated.
- Radio frequency energy, microwave energy, laser energy, extreme heat and extreme cold can be provided by the ablation device to kill the tissue. Certain procedures, such as cardiac procedures, are performed by selectively ablating the tissue. For example, in the case of a cardiac arrhythmia, the cardiac tissue is selectively ablated to eliminate the source of the arrhythmia. A popular minimally invasive procedure using radio frequency (RF) catheter ablation, has been used as has cryoablation in which the RF and cryogenic devices are arranged to provide very limited spot-sized lesions. As such, these conventional devices are not well suited for tissue ablation along a length, i.e. larger than a spot-sized lesion.
- In order to achieve freezing ablation along a length using conventional devices, a series of spot ablation lesions are created by moving the device tip located at the distal end of the device along the length to be ablated. The device typically includes a single cryogenic fluid lumen. Use of this arrangement can be time consuming, thereby prolonging procedure duration, and can result in an uneven ablation, reducing the effectiveness of the procedure. It would therefore be desirable to have a cryosurgical device that provides enhanced cooling capability for spot lesions, as well as the capability to create other than spot lesions.
- The present invention provides a device that provides enhanced cooling capability for spot lesions and the capability to create other than spot lesions, as well as a method for ablating tissue. In an exemplary embodiment the device includes a tip having a thermally transmissive region along a length thereof. The thermally transmissive region is operable at a temperature sufficient to cryosurgically ablate tissue in contact therewith. Fluid injection lumens are positioned within device so that the ends of the lumens are at different points along the length of the thermally transmissive region. Each of the ends are arranged to cool overlapping portions along the length of the thermally transmissive region when cryogenic fluid is ejected from the the fluid injection lumens.
- In an exemplary method for cryosurgically ablating tissue, a cryosurgical tip is positioned at tissue to be ablated, the tip having a thermally transmissive region along a length thereof. Cryogenic fluid is sequentially injected into the tip through multiple cryogenic fluid injection lumens terminating within the tip at different points along the length of the thermally transmissive region.
- A more complete understanding of the present invention, and the attendant advantages and features thereof, will be more readily understood by reference to the following detailed description when considered in conjunction with the accompanying drawings wherein:
- FIG. 1 is a schematic illustration of a cryosurgical system utilizing a cryogenic cooling structure constructed in accordance with the principles of the present invention;
- FIG. 2 is a diagram of a side view of an exemplar catheter arranged in accordance with the principles of the present invention;
- FIG. 3 is a block diagram of an arrangement of longitudinally spaced injection lumens and their corresponding cryogenic fluid control valves;
- FIG. 4 is a block diagram of an integrated fluid provisioning unit;
- FIG. 5 is a block diagram of a two port cryogenic fluid valve assembly;
- FIG. 6 is a cut away side view of an integrated fluid provisioning unit positioned within the inner volume of a handle;
- FIG. 7 is a cut away side view of an alternate arrangement of the present invention of thumbscrews positioned within the inner volume of a handle; and
- FIGS.8A-E show diagrammatic views of the thermally transmissive tip region at various times during the sequential operation of the valves.
- Referring now to the drawing figures in which like reference designators refer to like elements, there is shown in FIG. 1 a schematic illustration of a cryosurgical system utilizing a cryogenic cooling structure constructed in accordance with the principles of the present invention. The system includes a
fluid controller 10 coupled to theproximal end 12 of acatheter 14. Thecontroller 10 allows or causes cryogenic fluid to flow from a cryogenic fluid supply (not shown) through theproximal end 12 of thecatheter 14 to a thermallytransmissive tip region 16 positioned at the distal end of thecatheter 14. In operation, thefluid controller 10 is responsive to an input from a foot pedal or other human actuable switch to permit the flow of cryogenic fluid into thecatheter 14. One or more temperature sensors (not shown) in electrical communication with thecontroller 10 can be provided to regulate or terminate the flow of cryogenic fluid into thecatheter 14 by a predetermined temperature at a selected point or points on or within the catheter such as in thermallytransmissive region 16 is obtained. - The cryogenic fluid can be in a liquid or a gas state. An extremely low temperature can be achieved within the thermally
transmissive region 16 by cooling the fluid to a predetermined temperature prior to its introduction into thecatheter 14, by allowing a liquid state cryogenic fluid to boil or vaporize, or by allowing a gas state cryogenic fluid to expand. - Exemplary liquids include chlorodifluoromethane, polydimethylsiloxane, ethyl alcohol, HFCs such as AZ-20 (a 50-50 mixure of difluoromethane and pentafluoroethane sold by Allied Signal), nitrous oxide, and CFCs such as DuPont's Freon. Exemplary gases include nitrous oxide and carbon dioxide.
- FIG. 2 is a diagram of a side view of an
exemplar catheter 14 arranged in accordance with the principles of the present invention. As shown in FIG. 2, thecatheter 14 preferably includes anelectrical connector 18 and amechnaical connector 20 coupled to the thermallytransmissive region 16 via aflexible segment 24. - The
electrical connector 18 is coupled to thecontroller 10 and provides external connection points for electronic signals such as cryogenic fluid valve activation signals, ECG signals, temperature sensing signals and the like. Thecryogenic connector 20 preferably has an input opening 26 by which cryogenic fluid is input into thecatheter 14 and a cryogenic output opening 28 by which the cryogenic fluid is evacuated from thecatheter 14. - The
handle 22 is gripped by the user during operation and includes those control elements necessary for the user to “steer” the catheter inside the patient's body. Further, thehandle 22 an be arranged to define an inner volume in which cryogenic fluid valves are located. The arrangement and operation of the cryogenic fluid valves are discussed below in detail. -
Flexible segment 24 is generally arranged to include an outer fluid and gas impermeable sheath inside of which one or more flexible cryogenic fluid (or vapor) lumen are disposed for carrying the cryogenic fluid from thecontroller 10 to the thermallytransmissive region 16 and returning it. Preferably, the outer flexible sheath includes a return lumen or defines a volume for use as the return path for cryogenic fluid from the thermallytransmissive region 16 to the cryogenic output opening 28. Arrangements for providing a cryogenic fluid return lumen or using all or a portion of an inner volume of theflexible segment 24 as a return path for cryogenic fluid are known. - In operation, the cryogenic fluid is provided via the
controller 10 to the cryogenicfluid input opening 26. By applying a negative pressure to the cryogenic output opening 28, the cryogenic fluid is circulated through thehandle 22, through theflexible segment 24 to the thermallytransmissive tip region 16 where the fluid expands, boils, etc., thereby cooling the thermallytransmissive region 16. The spent vapor is returned through theflexible segment 24, through thehandle 22 and out the cryogenic fluid output opening 28. - The
catheter 14 is preferably arranged to include a plurality of cryogenic fluid injection lumens having respective openings longitudinally spaced at different points along the length L of the thermallytransmissive region 16. As discussed below in detail, the plurality of injection lumens can be individually arranged to span the entire length of thecatheter 14 from the input opening 26 to the thermallytransmissive region 16 or can be arranged as a single injection lumen from the input opening 26 to a cryogenic fluid distribution element provided in thehandle 22. - FIG. 3 shows a block diagram of an arrangement of the plurality of longitudinally spaced injection lumens and their corresponding cryogenic fluid control valves. Initially, it is noted that although FIG. 3 and the subsequent figures are arranged to show two or four injection lumens, it is contemplated that any quantity of injection lumen can be used subject to the desired length of the thermally
transmissive region 16, the maximum acceptable diameter of theflexible segment 24 for a particular application and the cryogenic fluid input capacity of the system. - As shown in FIG. 3, the
injection lumens fluid valve assembly 32 to the thermallytransmissive region 16 at the tip ofcatheter 14. Each of the injection lumens 30 a-30 d terminate at a different point along length L within thethermally transmissive region 16 or theshaft 24. For example, as shown in FIG. 3, theinjection lumen 30 a is the longest injection lumen, terminating substantially at the distal end of thecatheter 14. The injection lumen 30 b is shorter than theinjection lumen 30 a, theinjection lumen 30 c is shorter than the injection lumen 30 b and theinjection lumen 30 d is shorter than theinjection lumen 30 c such that it is positioned at a point along the length L within thethermally transmissive region 16 closer to thehandle 22 than the injection lumens 30 a-c. - The cryogenic
fluid valve assembly 32 is preferably comprised of an assembly fluid input 34 for each of the injection lumen (shown asassembly fluid inputs valves - As shown in FIG. 3, the cryogenic
fluid valve assembly 32 includes avalve processor 40 which receives n electronic actuation signals via the corresponding electronicactuation signal lines 42 and where n is the number of signal lines necessary to control actuation of the valves 38. Thevalve processor 40 can be any processing unit capable of actuating the valves 38. For example, the valves 38 can be arranged as piezo-electric valves which are actuable based on well-known piezo-electric principles. In this case, thevalve processor 40 operates to control the piezo-electric effect necessary to actuate the valves 38. The piezoelectric actuation method for the cryogenicfluid valve assembly 32 is preferred because theassembly 32 can be manufactured in a size small enough for placement within thehandle 22 of thecatheter 14. Of course, those skilled in the art understand that any suitable method for actuating the valves 38 can be used. - Also as shown in FIG. 3, the cryogenic fluid path includes a cryogenic fluid distributor44 having an
input 46 and one or more outputs 48 (shown in FIG. 3 asoutputs handle 22 of thecatheter 14. In the case where the cryogenic fluid distributor 44 is positioned within thehandle 22, theinput 46 is coupled to thecryogenic connector 20 by a tube suitable for carrying cryogenic fluid. - Although the cryogenic
fluid valve assembly 32 and the cryogenic fluid distributor 44 are shown as separate elements in FIG. 3, it is contemplated that the cryogenicfluid valve assembly 32 and the cryogenic fluid distributor 44 can be provided as a single unit. FIG. 4 is a block diagram showing the integratedfluid provisioning unit 50 which includes theinput 46, the valves 38 and the assembly fluid outputs 36. The integratedfluid provisioning unit 50 is preferably located within the inner volume of thehandle 22 but can also be located in other system components such as thecontroller 10. For example, the valves can be in a distal portion of the catheter. - Inclusion of the fluid distribution component, whether in the form of cryogenic fluid distributor44 as shown in FIG. 3 or within the integrated
fluid provisioning unit 50 as shown in FIG. 4, advantageously allows a single fluid connection between thecatheter 14 and thecontroller 10. - The present invention may also be arranged without the cryogenic fluid distributor44 or the integrated
fluid provisioning unit 50. FIG. 5 shows an example of a two port cryogenicfluid valve assembly 32 having twoassembly fluid inputs 34 a and 34 b and two assembly fluid outputs 36 a and 36 b coupled tocorresponding injection lumens 30 a and 30 b. Valves 38 are not shown in FIG. 5 for the sake of simplicity, it being understood that the valves 38 are included as described above with respect to the cryogenicfluid valve assembly 32. Using the arrangement shown in FIG. 5, corresponding input lumen 52 (shown in FIG. 5 asinput lumens controller 10 to the catheter 14 (via the cryogenic connector 20). An arrangement similar to the cryogenicfluid valve assembly 32 shown in FIG. 5 is implemented in the case where the cryogenic fluid distributor 44 is positioned in thecontroller 10 and the cryogenicfluid valve assembly 32 is located in thehandle 22. - FIG. 6 shows a cut away side view of an example of an integrated
fluid provisioning unit 50 positioned within theinner volume 54 of ahandle 22. As shown in FIG. 6, theinjection lumens 30 a and 30 b couple the integratedfluid provisioning unit 50 to the thermallytransmissive tip region 16. Areturn lumen 56 is provided for evacuating the cryogenic fluid from the thermallytransmissive tip region 16 for return to thefluid reservoir 10. Thereturn lumen 56 is coupled to thecryogenic output opening 28, the electronicactuation signal lines 42 are coupled to theelectrical connector 18 and thecryogenic fluid input 46 is coupled to theinput opening 26. - As discussed above with reference to FIGS. 3 and 4, it is contemplated that the cryogenic fluid distributor44 and/or the cryogenic
fluid valve assembly 32 can be located within theinner volume 54 of thehandle 22. - FIG. 7 shows a cut away side view of an alternate arrangement of the present invention in which the cryogenic fluid flow is manually actuated by
thumbscrew valves 58 a and 58 b. As shown in FIG. 7, the human actuable portion of thethumbscrew valves 58 a and 58 b protrude through the outer surface of the handle 22 a asthumbscrews 60 a and 60 b, respectively. Thethumbscrew valves 58 a and 58 b are manually adjustable by the user via a correspondingthumbscrew 60 a and 60 b to open or close the cryogenic fluid path between theinput lumens catheter 14. - The operation of the
catheter 14 is described with reference to FIGS. 8A-8E. Each of FIGS. 8A-8E show a diagrammatic view of the thermallytransmissive tip region 16 at various times during the sequential operation of the valves 38 a-38 d. FIG. 8A shows the thermallytransmissive tip region 16 at a state in which none of valves 38 a-38 d have been opened, i.e. cryogenic fluid is not flowing in the injection lumens 30 a-30 d. Thefreeze zones transmissive tip region 16 corresponding to the distal terminus of a corresponding injection lumen 30 a-30 d. It is noted that the freeze zones 62 a-62 d represent approximate areas along the surface of the thermallytransmissive tip region 16 and do not correspond to actual elements. As such, the size and specific location of the freeze zones 62 a-62 d can vary and are substantially related to the corresponding distal terminus of the injection lumen 30 a-30 d. - Upon actuation of the device, the valves38 a-38 d are sequentially opened and closed. FIG. 8B shows cryogenic fluid in
injection lumen 30 a causing a freezing condition around thefreeze zone 62 a. As such, thearea 64 a on the exterior of the thermallytransmissive tip region 16 is cooled by the ejection of the cryogenic fluid from the distal terminus of theinjection lumen 30 a such that thearea 64 a is cooled to an extent sufficient for the application of cryosurgical ablation. At a point t in time after thevalve 38 a is opened, thevalve 38 a is closed and the valve 38 b is opened, causing cryogenic fluid to be ejected from the distal end of the injection lumen 30 b in the thermallytransmissive tip region 16. As a result, the area 64 b around the freeze zone 62 b is created which overlaps thearea 64 a and is chilled to a point sufficient for cryosurgical ablation. - FIG. 8D and FIG. 8E are diagrams showing the expansion of the freeze area to include overlapping
areas valves transmissive tip region 16. - The freeze area along length L is advantageously accomplished by sequentially operating the valves38 a-38 d in a manner which does not require an excessive cryogenic fluid flow rate which would otherwise create a positive pressure inside the
catheter 14. The sequential operation is preferably controlled by a microprocessor or other central processing unit to electronically instruct thevalve processor 40 to sequentially actuate the valves 38 a-38 d. Electronic control using thevalve processor 40 allows precise valve actuation control for sequencing and valve actuation duration. - For example, using a 7
French size catheter 14, it has been found that 1300 cubic centimeters per minute of coolant can create a 28 millimeter long freeze area. By sequentially applying the 1300 cubic centimeter per minute coolant to each of the four injection lumens 30 a-30 d in a manner which causes an overlap of the freeze area, a freeze area of approximately 100 millimeters in length can be created. - As such, a freeze length L can be achieved using a very small cryogenic fluid flow rate as compared with known devices (3800 cubic feet per minute to achieve a 60 millimeter freeze length using a single injection lumen versus 1300 cubic centimeter per minutes cryogenic fluid flow rate to achieve a 100 millimeter freeze length L). The arrangement of the present invention advantageously conserves cryogenic fluid while providing an extended freeze length L as compared with known similarly sized devices.
- As eluded to above, in order to preserve the advantage of cryoablation by adhering the thermally
transmissive tip region 16 to the patient's tissue during the ablation procedure, the ejection of cryogenic fluid from one injection lumen should begin after cryogenic fluid ejection is terminated in the previous injection lumen in the sequence, but before the previous areas dislodge, i.e. thaw, from the tissue. Because the sequential application of cryogenic fluid is used, the total procedure time becomes t times m where m is the number of freezing areas (and injection tubes). - It is also contemplated that multiple lumens can be logically grouped and activated at substantially the same time, subject to maintaining a cryogenic fluid flow rate which can be evacuated from the
catheter 14 while maintaining a negative pressure within thecatheter 14. For example,valves valves 38 b and 38 d opened at substantially the same time. This technique shortens the cryoablation procedure time as compared with the discreet sequential operation of the valves 38 a-38 d described above while still maintaining a safe operating environment, for example, 2600 cubic centimeters per minute in a 7 French size catheter. - Another implementation of the device of the present invention permits use as a mapping and/or selective ablation zone device. Because the freeze area length along the tip of the device is extremely elongated as compared with known devices and because particular areas of the device can be selectively cooled (areas64 a-64 d), the device of the present invention can be used to perform cold mapping to detect tissue regions, such as cardiac tissue regions, which if ablated will eliminate an arrhythmia. Each of areas 64 a-64 d can be cooled to determine which areas, if any, will improve or eliminate the arrhythmia.
- The elongated freeze length L advantageously allows individual areas to be cooled without the need to relocate the thermally
transmissive tip region 16 to another tissue point. Once an area is identified as suitable for ablation, the particular valve or valves 38 are opened and the specific section(s) of the thermallytransmissive tip region 16 cooled. This arrangement advantageously minimizes tissue destruction such as myocardial tissue destruction and saves time by avoiding the need to repeatedly thaw and relocate the thermallytransmissive tip region 16. - Although the present invention is described above with respect to a catheter, it is contemplated that a device constructed in accordance with the principles of the present invention can take other forms, including but not limited to a rigid probe.
- The present invention advantageously provides a device and method which provides an elongated freeze length within the thermally transmissive tip region in a manner in which specific areas in the thermally transmissive tip region can be cooled or sequentially cooled to provide an elongated freeze length. The arrangement of the present invention is advantageously provided in a manner which maintains a usable device size and which maintains a safe operating mode by maintaining a negative pressure within the device.
- It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described herein above. In addition, unless mention was made above to the contrary, it should be noted that all of the accompanying drawings are not to scale. A variety of modifications and variations are possible in light of the above teachings without departing from the scope and spirit of the invention, which is limited only by the following claims.
Claims (24)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/371,023 US20030130652A1 (en) | 2001-10-09 | 2003-02-20 | Cryosurgical ablation device having sequential injection and method therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/973,595 US6579287B2 (en) | 2001-10-09 | 2001-10-09 | Cryosurgical ablation device having sequential injection and method therefor |
US10/371,023 US20030130652A1 (en) | 2001-10-09 | 2003-02-20 | Cryosurgical ablation device having sequential injection and method therefor |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/973,595 Continuation US6579287B2 (en) | 2001-10-09 | 2001-10-09 | Cryosurgical ablation device having sequential injection and method therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030130652A1 true US20030130652A1 (en) | 2003-07-10 |
Family
ID=25521046
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/973,595 Expired - Lifetime US6579287B2 (en) | 2001-10-09 | 2001-10-09 | Cryosurgical ablation device having sequential injection and method therefor |
US10/371,023 Abandoned US20030130652A1 (en) | 2001-10-09 | 2003-02-20 | Cryosurgical ablation device having sequential injection and method therefor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/973,595 Expired - Lifetime US6579287B2 (en) | 2001-10-09 | 2001-10-09 | Cryosurgical ablation device having sequential injection and method therefor |
Country Status (2)
Country | Link |
---|---|
US (2) | US6579287B2 (en) |
WO (1) | WO2003030710A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030125652A1 (en) * | 2001-08-27 | 2003-07-03 | Porrata Humberto Luis | Adaptable apparatus and method for treating carpal tunnel syndrome |
US20030130604A1 (en) * | 2001-08-27 | 2003-07-10 | Porrata Humberto Luis | Adjustable apparatus and method for treating carpal tunnel syndrome |
US20030130692A1 (en) * | 2001-08-27 | 2003-07-10 | Porrata Humberto Luis | Automatic apparatus and method for treating carpal tunnel syndrome |
US20030130691A1 (en) * | 2001-08-27 | 2003-07-10 | Porrata Humberto Luis | Configurable apparatus and method for treating carpal tunnel syndrome |
US20030130690A1 (en) * | 2001-08-27 | 2003-07-10 | Porrata Humberto Luis | Non-invasive apparatus and method for treating carpal tunnel syndrome |
US11648047B2 (en) | 2017-10-06 | 2023-05-16 | Vive Scientific, Llc | System and method to treat obstructive sleep apnea |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7004936B2 (en) | 2000-08-09 | 2006-02-28 | Cryocor, Inc. | Refrigeration source for a cryoablation catheter |
US7617005B2 (en) * | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US7004937B2 (en) * | 2002-07-31 | 2006-02-28 | Cryocor, Inc. | Wire reinforced articulation segment |
US20040034365A1 (en) * | 2002-08-16 | 2004-02-19 | Lentz David J. | Catheter having articulation system |
US6955673B2 (en) * | 2002-08-16 | 2005-10-18 | Cryocor, Inc. | Heat transfer segment for a cryoablation catheter |
US20040034344A1 (en) * | 2002-08-16 | 2004-02-19 | Eric Ryba | Tip pressure monitoring for cryoablation catheters |
US6796979B2 (en) * | 2002-12-11 | 2004-09-28 | Cryocor, Inc. | Coaxial catheter system for performing a single step cryoablation |
US6824543B2 (en) | 2002-12-11 | 2004-11-30 | Cryocor, Inc. | Guidance system for a cryocatheter |
US6893433B2 (en) * | 2002-12-11 | 2005-05-17 | Cryocor, Inc. | System and method for performing a single step cryoablation |
US20040116921A1 (en) * | 2002-12-11 | 2004-06-17 | Marshall Sherman | Cold tip rf/ultrasonic ablation catheter |
US7195625B2 (en) | 2002-12-11 | 2007-03-27 | Cryocor, Inc. | Catheter system for performing a single step cryoablation |
US6981382B2 (en) * | 2003-07-24 | 2006-01-03 | Cryocor, Inc. | Distal end for cryoablation catheters |
US20050027289A1 (en) * | 2003-07-31 | 2005-02-03 | Thomas Castellano | Cryoablation systems and methods |
US20050075654A1 (en) * | 2003-10-06 | 2005-04-07 | Brian Kelleher | Methods and devices for soft tissue securement |
US7070594B2 (en) * | 2004-02-10 | 2006-07-04 | Cryocor, Inc. | System and method for assessing ice ball formation during a cryoablation procedure |
US20050198972A1 (en) * | 2004-03-10 | 2005-09-15 | Lentz David J. | Pressure-temperature control for a cryoablation catheter system |
US7727228B2 (en) * | 2004-03-23 | 2010-06-01 | Medtronic Cryocath Lp | Method and apparatus for inflating and deflating balloon catheters |
US7156840B2 (en) * | 2004-06-29 | 2007-01-02 | Cryocor, Inc. | Pressure monitor for cryoablation catheter |
US7163535B2 (en) * | 2004-06-30 | 2007-01-16 | Cryocor, Inc. | System for detecting leaks and occlusions in a cryoablation catheter |
US7357797B2 (en) * | 2004-06-30 | 2008-04-15 | Cryocor, Inc. | System and method for varying return pressure to control tip temperature of a cryoablation catheter |
US8162929B2 (en) * | 2007-06-01 | 2012-04-24 | Boston Scientific Scimed, Inc. | Cryoablation segment for creating linear lesions |
US8915908B2 (en) * | 2009-03-20 | 2014-12-23 | Atricure, Inc. | Cryogenic probe |
US10058675B2 (en) | 2009-09-21 | 2018-08-28 | Cook Regentec Llc | Infusion catheter tip for biologics with reinforced external balloon valve |
US8647311B2 (en) * | 2009-09-21 | 2014-02-11 | Translational Biologic Infusion Catheter, Llc | Biologics infusion system |
US8790298B2 (en) | 2009-09-21 | 2014-07-29 | Translational Biologic Infusion Catheter, Llc | Infusion catheter tip for biologics |
US10155099B2 (en) | 2009-09-21 | 2018-12-18 | Cook Regentec Llc | Method for infusing stem cells |
US9220555B2 (en) | 2010-10-28 | 2015-12-29 | Medtronic Ablation Frontiers Llc | Cryo-ablation device with deployable injection tube |
US9566105B2 (en) * | 2012-02-07 | 2017-02-14 | Cpsi Holdings Llc | Dual thermal ablation device and method of use |
US9867660B2 (en) * | 2013-03-13 | 2018-01-16 | Medtronic Cryocath Lp | Vein occlusion assessment using temperature |
US9131975B2 (en) | 2013-03-15 | 2015-09-15 | Warsaw Orthopedic, Inc. | Nerve and soft tissue ablation device |
US9241754B2 (en) | 2013-03-15 | 2016-01-26 | Warsaw Orthopedic, Inc. | Nerve and soft tissue ablation device |
US9023022B2 (en) | 2013-03-15 | 2015-05-05 | Warsaw Orthopedic, Inc. | Nerve and soft tissue ablation device having release instrument |
US9023023B2 (en) | 2013-03-15 | 2015-05-05 | Warsaw Orthopedic, Inc. | Nerve and soft tissue ablation device |
US9186197B2 (en) | 2013-03-15 | 2015-11-17 | Warsaw Orthopedic, Inc. | Nerve and soft tissue ablation device for treating pain |
US9033966B2 (en) | 2013-03-15 | 2015-05-19 | Warsaw Orthopedic, Inc. | Nerve and soft tissue ablation device |
US9198707B2 (en) | 2013-03-15 | 2015-12-01 | Warsaw Orthopedic, Inc. | Nerve and soft tissue ablation device and method |
US9895190B2 (en) | 2014-04-28 | 2018-02-20 | Warsaw Orthopedic, Inc. | Devices and methods for radiofrequency ablation having at least two electrodes |
US10631893B2 (en) | 2015-07-10 | 2020-04-28 | Warsaw Orthopedic, Inc. | Nerve and soft tissue removal device |
WO2018087563A1 (en) * | 2016-11-14 | 2018-05-17 | Nitro Medical Limited | Cryoablation |
AU2020232595A1 (en) | 2019-03-01 | 2021-09-16 | Rampart Health, L.L.C. | Pharmaceutical composition combining immunologic and chemotherapeutic method for the treatment of cancer |
JP2024506914A (en) | 2021-02-12 | 2024-02-15 | ランパート ヘルス リミテッド ライアビリティー カンパニー | Therapeutic compositions and methods combining multiplex immunotherapy and cancer vaccines for the treatment of cancer |
CN113476134B (en) * | 2021-06-30 | 2022-06-24 | 海杰亚(北京)医疗器械有限公司 | Method and device for adjusting pressure in working medium storage tank |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6355029B1 (en) * | 1997-12-02 | 2002-03-12 | Cryovascular Systems, Inc. | Apparatus and method for cryogenic inhibition of hyperplasia |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5147355A (en) | 1988-09-23 | 1992-09-15 | Brigham And Womens Hospital | Cryoablation catheter and method of performing cryoablation |
US5281215A (en) | 1992-04-16 | 1994-01-25 | Implemed, Inc. | Cryogenic catheter |
US5281213A (en) | 1992-04-16 | 1994-01-25 | Implemed, Inc. | Catheter for ice mapping and ablation |
US5423807A (en) | 1992-04-16 | 1995-06-13 | Implemed, Inc. | Cryogenic mapping and ablation catheter |
NL9301851A (en) | 1993-10-26 | 1995-05-16 | Cordis Europ | Cryo-ablation catheter. |
GB2283678B (en) | 1993-11-09 | 1998-06-03 | Spembly Medical Ltd | Cryosurgical catheter probe |
US6235019B1 (en) | 1997-02-27 | 2001-05-22 | Cryocath Technologies, Inc. | Cryosurgical catheter |
US6106518A (en) | 1998-04-09 | 2000-08-22 | Cryocath Technologies, Inc. | Variable geometry tip for a cryosurgical ablation device |
US6280439B1 (en) | 1999-07-12 | 2001-08-28 | Cryocath Technologies, Inc. | Adjustable position injection tubing |
US6270493B1 (en) | 1999-07-19 | 2001-08-07 | Cryocath Technologies, Inc. | Cryoablation structure |
-
2001
- 2001-10-09 US US09/973,595 patent/US6579287B2/en not_active Expired - Lifetime
-
2002
- 2002-09-25 WO PCT/US2002/030528 patent/WO2003030710A2/en not_active Application Discontinuation
-
2003
- 2003-02-20 US US10/371,023 patent/US20030130652A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6355029B1 (en) * | 1997-12-02 | 2002-03-12 | Cryovascular Systems, Inc. | Apparatus and method for cryogenic inhibition of hyperplasia |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030125652A1 (en) * | 2001-08-27 | 2003-07-03 | Porrata Humberto Luis | Adaptable apparatus and method for treating carpal tunnel syndrome |
US20030130604A1 (en) * | 2001-08-27 | 2003-07-10 | Porrata Humberto Luis | Adjustable apparatus and method for treating carpal tunnel syndrome |
US20030130692A1 (en) * | 2001-08-27 | 2003-07-10 | Porrata Humberto Luis | Automatic apparatus and method for treating carpal tunnel syndrome |
US20030130691A1 (en) * | 2001-08-27 | 2003-07-10 | Porrata Humberto Luis | Configurable apparatus and method for treating carpal tunnel syndrome |
US20030130690A1 (en) * | 2001-08-27 | 2003-07-10 | Porrata Humberto Luis | Non-invasive apparatus and method for treating carpal tunnel syndrome |
US6953440B2 (en) | 2001-08-27 | 2005-10-11 | Porrata Group Llp | Automatic apparatus and method for treating carpal tunnel syndrome |
US7182741B2 (en) | 2001-08-27 | 2007-02-27 | Porrata Group Llc | Adaptable apparatus and method for treating carpal tunnel syndrome |
US7344511B2 (en) | 2001-08-27 | 2008-03-18 | Porrata Group Llc | Adjustable apparatus and method for treating carpal tunnel syndrome |
US7476207B2 (en) | 2001-08-27 | 2009-01-13 | Porrata Group Llc | Configurable apparatus and method for treating carpal tunnel syndrome |
US11648047B2 (en) | 2017-10-06 | 2023-05-16 | Vive Scientific, Llc | System and method to treat obstructive sleep apnea |
Also Published As
Publication number | Publication date |
---|---|
WO2003030710A3 (en) | 2003-11-27 |
WO2003030710A2 (en) | 2003-04-17 |
WO2003030710B1 (en) | 2004-01-29 |
US6579287B2 (en) | 2003-06-17 |
US20030069568A1 (en) | 2003-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6579287B2 (en) | Cryosurgical ablation device having sequential injection and method therefor | |
EP1129669B1 (en) | Cryoablation catheter with an expandable cooling chamber | |
US5108390A (en) | Flexible cryoprobe | |
US6547785B1 (en) | Cryoablation catheter for long lesion ablations | |
US12127786B2 (en) | Vein occlusion assessment using temperature | |
EP0655225B1 (en) | Cryo-ablation catheter | |
US6497703B1 (en) | Cryoablation catheter for long lesion ablations | |
US5899898A (en) | Cryosurgical linear ablation | |
CA2393228C (en) | Catheter with cryogenic and electrical heating ablation | |
US8162929B2 (en) | Cryoablation segment for creating linear lesions | |
US7641679B2 (en) | Cryosurgical fluid supply | |
US6551309B1 (en) | Dual action cryoprobe and methods of using the same | |
EP2704653B1 (en) | Adiabatic cooling system for medical devices | |
US5735845A (en) | Method of treating the prostate using cryosurgery | |
EP1881795A1 (en) | Contact assessment of balloon catheters | |
WO2014138867A1 (en) | Cryoablation device and method for improved safety and efficacy | |
EP1011489B1 (en) | Apparatus for linear ablation | |
US20020177845A1 (en) | Cryoablation catheter with an improved gas expansion chamber | |
US20070149958A1 (en) | Cryoprobe with exhaust heater |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: LA FINANCIERE DU QUEBEC, QUEBEC Free format text: SECURITY INTEREST;ASSIGNOR:CRYOCATH TECHNOLOGIES, INC.;REEL/FRAME:015035/0808 Effective date: 20040211 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: CRYOCATH TECHNOLOGIES INC., CANADA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:INVESTISSEMENT QUEBEC;REEL/FRAME:022320/0787 Effective date: 20090220 Owner name: CRYOCATH TECHNOLOGIES INC.,CANADA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:INVESTISSEMENT QUEBEC;REEL/FRAME:022320/0787 Effective date: 20090220 |
|
AS | Assignment |
Owner name: MEDTRONIC CRYOCATH LP, CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CRYOCATH TECHNOLOGIES INC.;REEL/FRAME:023119/0651 Effective date: 20090814 Owner name: MEDTRONIC CRYOCATH LP,CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CRYOCATH TECHNOLOGIES INC.;REEL/FRAME:023119/0651 Effective date: 20090814 |